+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of several investigational long-acting antibody treatments, both alone and in combination, for adults with moderately to severely active ulcerative colitis UC. This Phase 2 platform study involves multiple centers and aims to improve treatment options for this condition by comparing different therapies. The study consists of two parts. Part A was an open-label phase assessing safety and early effectiveness of three monotherapies, which completed enrollment in April 2026. Part B is currently enrolling and is a randomized, placebo-controlled phase testing three monotherapies and three combination therapies against placebo. Participants will receive intravenous induction and subcutaneous maintenance treatments, with different dosing regimens evaluated over time. Participants will be monitored through regular assessments including endoscopy and histology to measure disease activity and response. The main outcomes include clinical remission and histologic improvement after 12 weeks, with longer-term remission assessed up to 48 weeks. Safety and efficacy data will be collected throughout, with treatment duration and follow-up determined by study protocol. The total study completion is expected by March 2028.

Age: 18Years - 75YearsAll GendersPhase 2
276 locations
E

Actively Recruiting

Researchers are evaluating how efgartigimod affects thyroid function in adults with Graves Disease GD, focusing on its safety, tolerability, and impact on antibody levels and immune response. This Phase 3 study compares efgartigimod with placebo in adults whose GD is not adequately controlled with antithyroid drugs, aiming to better understand its effects on thyroid hormone levels and disease control. Participants will be randomly assigned to receive either efgartigimod PH20 subcutaneous injections via prefilled syringe or placebo during the initial double-blinded treatment period part A and treatmentobservation period part B. Those who respond may continue to an open-label treatmentobservation phase part C receiving efgartigimod. Treatment and observation durations vary, with total participation lasting from approximately 63 to 135 weeks depending on individual response. During the study, participants will undergo regular assessments of thyroid hormone levels fT3, fT4, TSH, antibody levels, and immune responses to evaluate treatment effects. Safety and tolerability will be closely monitored, and researchers will track changes in thyroid-related symptoms and quality of life. The main outcome is the percentage of participants achieving normal thyroid hormone levels without antithyroid drugs by week 24. Participants will be followed for up to nearly three years to observe long-term effects and safety.

Age: 18Years +All GendersPhase 3
51 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.

Age: 18Years +All GendersPhase 3
356 locations
P

Actively Recruiting

This research aims to evaluate the safety, effectiveness, and how the body processes ferumoxytol for treating iron deficiency anemia IDA in children aged 2 to under 18 years. The study includes male and female pediatric subjects with IDA or those considered at risk of developing IDA by their clinician, regardless of cause, except for those with chronic kidney disease CKD, who are studied separately. Participants will be randomly assigned in a 21 ratio to receive either ferumoxytol or iron sucrose. Ferumoxytol is given as two intravenous doses of 7 mg iron per kg, with a maximum of 510 mg per dose the first dose is on Day 1 and the second dose is 2 to 8 days later. Iron sucrose is given as five intravenous doses of 4 mg iron per kg, with a maximum of 200 mg per dose the first dose is on Day 1 and the remaining doses are given at least once per week and up to three times per week. Participants are monitored for one hour after each infusion. Throughout the study, which lasts up to 5 weeks, researchers will assess hemoglobin levels, check for side effects or adverse events, and perform other safety tests. The main outcome measured is the change in hemoglobin from the start to Week 5. Additional safety assessments include tracking any new or special adverse events up to 49 days after treatment begins.

Age: 2Years - 17YearsAll GendersPhase 3
15 locations
P

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and pharmacokinetics of ferumoxytol compared to iron sucrose in children with chronic kidney disease CKD who have iron deficiency anemia IDA or are at risk of developing it. The study focuses on pediatric patients aged 2 to under 18 years and aims to better understand ferumoxytols profile in this group. This Phase 3, randomized, open-label study involves multiple centers and approximately 125 participants. Participants will be randomly assigned in a 21 ratio to receive either ferumoxytol or iron sucrose. Those in the ferumoxytol group will get two intravenous infusions of 7.0 mg Fekg up to 510 mg per dose, the first on Day 1 and the second 2 to 8 days later. Those receiving iron sucrose will have dosing based on dialysis status hemodialysis-dependent patients receive 2 mg Fekg on consecutive dialysis sessions for 10 doses, and non-hemodialysis-dependent or peritoneal dialysis-dependent patients receive 4 mg Fekg up to three times per week for 5 doses, with total maximum doses capped at 1000 mg. The study lasts up to 7 weeks, including a 2-week screening period and a 5-week treatment period. Researchers will monitor hemoglobin changes, adverse events, and special safety concerns during 49 days of follow-up. Assessments include blood tests to measure hemoglobin and iron levels, safety evaluations, and pharmacokinetic and pharmacodynamic analyses. This helps determine how participants respond and tolerate the treatments over time.

Age: 2Years - 17YearsAll GendersPhase 3
21 locations
S

Actively Recruiting

Researchers are evaluating the ContraBand12 device, a transcatheter constriction implant placed in the left and right branch pulmonary arteries to treat left-sided heart failure. This early feasibility study aims to assess how the device reduces pulmonary artery pressure and improves heart function during exercise, potentially enhancing physical capacity and prognosis for heart failure patients. The study is prospective, multi-center, interventional, open-label, and single-arm, focusing on safety and device feasibility. The intervention involves percutaneous implantation of the ContraBand devices through right heart catheterization. The device works by locally narrowing the pulmonary arteries, which lowers distal systolic pulmonary artery pressure and reduces the rise in pulmonary capillary wedge pressure during exercise. This change reflects improved left ventricular filling and cardiac output. There is no comparator group all participants receive the ContraBand implant. Participants will be monitored for device- or procedure-related major adverse events within 30 days and procedural success during implantation. Assessments include six-minute walk test distance and heart function measures. The study enrolls adults aged 18 to 85 with symptomatic left heart failure, and participants will be followed for safety and functional outcomes. The total study duration extends up to the end date in 2032, with detailed follow-up to evaluate feasibility and safety.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
12 locations
T

Actively Recruiting

Researchers are examining the feasibility of implementing digitally supported physical rehabilitation for cancer patients during and after systemic treatment. This multinational study involves five countries in the South Baltic region and aims to improve accessibility to rehabilitation services, which are important for maintaining physical function and quality of life in cancer survivors. The study addresses barriers such as distance to facilities, busy treatment schedules, and limited internet access, with the goal of enhancing rehabilitation reach and sustainability across different healthcare settings. The intervention consists of needs-based digital rehabilitation programs lasting from 8 to 16 weeks, delivered by trained healthcare professionals. Each participating site selects a digital solution tailored to local needs, offering either fully or partially digital rehabilitation during systemic cancer treatment and after treatment completion. The study includes two separate feasibility trials one for patients currently receiving systemic therapy and another for those who have recently completed treatment or are on maintenance therapy. Participants will engage in individualized goal setting and rehabilitation guided by healthcare professionals, with assessments conducted throughout the intervention period. Data collection includes patient-reported outcomes, therapist perspectives, and resource use, all stored securely in a database. The study will measure factors such as reach, effectiveness, adoption, implementation, and maintenance of digital rehabilitation using the RE-AIM framework. Safety, drop-outs, and economic aspects will also be monitored over approximately 4 to 12 weeks for patients and up to about one year for therapists.

Age: 18Years +All GendersPhase Not Applicable
5 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
L

Actively Recruiting

Researchers are studying the long-term safety and effectiveness of pembrolizumab MK-3475 in participants with advanced tumors or blood cancers who were part of previous pembrolizumab-based studies. This extension study includes participants currently receiving treatment or in follow-up from parent trials. It consists of three phases the First Course Phase, Survival Follow-up Phase, and Second Course Phase, depending on the participants status at the end of their previous study. Participants may receive pembrolizumab alone or combined with standard of care treatments, lenvatinib, or other study drugs like olaparib and MK-4280, delivered mainly by intravenous infusion or oral capsules. Dosing schedules vary, including pembrolizumab administered every 3 or 6 weeks for up to 35 or 17 doses depending on the phase. Some participants may take lenvatinib orally daily, timed with pembrolizumab infusions, while others may receive investigational combination therapies or standard care treatments according to their parent studys protocol. During the study, participants will have regular infusions or oral dosing and be monitored over several years for overall survival and other outcomes like progression-free survival and adverse events. Researchers will assess safety and efficacy for up to approximately 10 years, with detailed tracking of side effects and treatment discontinuations. Study visits and assessments will be conducted to evaluate organ function, disease status, and any treatment-related effects throughout the study duration.

Age: 18Years +All GendersPhase 3
782 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of LY4268989 compared to a placebo in adults with moderately to severely active ulcerative colitis UC. The study involves participants aged 18 to 80 who have had UC for at least three months and have active symptoms confirmed by specific scoring methods. This Phase 2 clinical trial is sponsored by Eli Lilly and Company and focuses on treatment effects over a long period. Participants will receive oral doses of LY4268989 or a matching placebo in a randomized, double-blind design. The study includes two experimental dose groups of LY4268989 and one placebo group. Treatment and evaluation will continue for up to approximately 108 weeks, excluding the screening period. During the trial, participants will be regularly assessed for clinical remission and response using the Modified Mayo Score at weeks 10 and 52. Researchers will monitor symptomatic responses and drug levels in the blood up to week 52. Safety and effectiveness data will be collected throughout the study, with the overall duration lasting up to about two years.

Age: 18Years - 80YearsAll GendersPhase 2
258 locations

1-10 of 13

1